Published

631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Unknown
Date: 2025-07-31
Source: Europe PMC
DOI: Unavailable
PubMed: Unavailable

Authors

Watch author

Topics and keywords

psilocybin Depression Treatment-Resistant Depression Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17 Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARASAIMSARA Journal · 2026-06-14 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-06-04 Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic PotentialDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21 Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybinJournal of Pre-Clinical and Clinical Research · 2026-05-11 Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic ReviewResearch Square · 2026-05-10 Does Psilocybin Require Psychedelic Effects to Treat Depression? A4-Week, Double-Blind, Proof-of-Concept Randomized Controlled TrialClinicalTrials.gov · 2026-05-06 Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative ReviewJournal of Education Health and Sport · 2026-05-06